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Adaptive cell immunotherapy with the use of chimeric receptors leads to the best and most speciﬁc response against tumors.
Chimeric receptors consist of a signaling fragment, extracellular spacer, costimulating domain, and an antibody. Antibodies cause
immunogenicity; therefore, VHH is a good replacement for ScFv in chimeric receptors. Since peptide sequences have an inﬂuence
on chimeric receptors, the eﬀect of peptide domains on each other’s conformation were investigated. CD3Zeta, CD28, VHH
and CD8α, and FcgIIα are used as signaling moieties, costimulating domain, antibody, and spacers, respectively. To investigate
the inﬂuence of the ligation of spacers on the conformational structure of VHH, models of VHH were constructed. Molecular
dynamicssimulationwasruntostudytheinﬂuenceofthepresenceofspacersontheconformationalchangesinthebindingsitesof
VHH. Root mean square deviation and root mean square ﬂuctuation of critical segments in the binding site showed no noticeable
diﬀerences with those in the native VHH. Results from molecular docking revealed that the presence of spacer FcgIIα causes an
increasingeﬀectonVHHwithMUC1interaction.EachoftheconstructswastransformedintotheJurkatE6.1.Expressionanalysis
and evaluation of their functions were examined. The results showed good expression and function.
1.Introduction
Adaptive cancer immunotherapy can cause stimulation of
the immune system in diﬀerent ways, thus leading to the
prevention of cancerous cellular growth [1–3]. Regarding
the important role of T cells in cellular immunity against
tumors, various strategies have been applied to increase
the performance and speciﬁc activation of T cells against
tumors [4–7]. The aim of T-cell engineering is modiﬁcation
of chimeric T-cell receptors (chTCRs), in order to achieve
high chimeric antigen receptor (CAR) expression. In one
kind of chimeric receptor, independent of MHC for antigen
recognition, a monoclonal antibody with high speciﬁcity
for the target antigen was used. In this way, the resulting
chimeric fragment had all the properties required to produce
the best response against a tumor, such as: penetration into
the tumor, cytokine secretion, cytotoxicity, and good speci-
ﬁcity against cancerous antigens. The three main moieties
of chTCR are the signaling domain, extracellular spacer
domain, and the molecule attached to the antigen [8–10].
The importance of chTCR is that the speciﬁc antibody in
its structure activates the immune system against target
molecules on tumors. In other words, they cause tumor-
speciﬁc immunity.
Therefore, the main property of chTCR is its killing/
eﬀector action against the target protein, independent of
a monoclonal antibody against a speciﬁc tumor antigen.
chTCRs are in fact artiﬁcial receptors in which an antibody
recognizes the speciﬁc tumor antigen that is attached to a T-
cell triggering domain.
In this study, the antibody part of the camelid VHH
fragmenttogetherwithCD3Zetaasthesignalingdomainand2 Journal of Biomedicine and Biotechnology
CD8α and FcgIIα representing the spacers were used as dif-
ferent parts of the chimeric receptor. In Chimeric receptors,
theheterogenousproteinfragmentsarefusedtogether;hence
they can aﬀect each other’s function and structure. Because
oftheimportanceofthepreservationofantibodyactivity,the
selectionofthetypeofspacerhasanexceptionalimportance.
Therefore, accuracy of results derived from the theoretical
studies can have an enormous impact. For this purpose, two
spacers were selected. In the theoretical phase of the study,
their eﬀects on antibody structure were studied, and with
regard to both simulation parameters, diﬀerent chimeric
constructswereconstructed.Twochimericfragmentscarried
by the PCZ (pcDNA3.1Hygro+ CD28Zeta) vector were then
expressed in Jurkat cell lines, and the theoretical ﬁndings
were subsequently compared with the experimental data.
Comparative studies involved an evaluation of the interac-
tion strength during the binding process of the proteins that
have a signiﬁcant importance in understanding the binding
process,thusenhancingtheabilityofdesigningheterogenous
proteins as chimeric receptor structures. Besides disulﬁde
bonds, electrostatic forces are also responsible for protein
recognition and binding, and as such have long-range eﬀects
on chimeric proteins’ structure, function, and interaction
with ligands, such as the peptide antigen fragments. There-
fore,calculationofelectrostaticpotentialandinvestigationof
factors which aﬀect these forces are of vital importance [11–
15].
In previous work it was shown that the results from
docking of MUC1 with diﬀerent type of antibodies are in
goodagreementwiththeattainedresultsfromdynamicforce
spectroscopy (DFS); and these results present molecular
docking simulation as a powerful method to prediction of
binding sites in molecular recognition [16].
Due to the fact that spacer and ligand (antigen) binding
involves hydrophobic forces as well as hydrogen bonds, both
of which act in short range, structural rearrangement, and
regulation of speciﬁc and correct binding can occur, thus
leading to a new antibody and spacer structure. Therefore,
the eﬀect of protein sequences on the antibody during
this binding process and, eventually, their functions are
highly signiﬁcant. Furthermore, the results of the theoretical
studies must be monitored and evaluated in parallel with the
experimental procedures, because increases in VHH aﬃnity
and the target peptide in the antigen are not objective,
and after binding, eﬀective signal transduction through
the inserted spacer in the chimeric structure must occur.
Therefore, in this study, the importance of spacer structure,
as spacer domain, for better antibody domain exposure and
its eﬀect on VHH conformation with regard to interaction
with MUC1 were investigated.
2.MaterialsandMethods
2.1. Homology Modeling. The homology study was per-
formed using the MODELLER program version 9v2 [17].
The models were constructed on the basis of the camelid
heavy-chain antibody (with PDB code: 1G6V) for VHH, the
T-cell coreceptor, CD8α (with PDB code: 1AKJ) and the
crystal structure of α-glucokinase for spacer1, the ERBB-2
receptor protein-tyrosine kinase (with PDB code: 1IIJ), and
the membrane protein stannin (SNN) for spacer2.
2.2. Molecular Dynamics Simulation. MD simulation was
performed using the AMBER9 program [18] at the Depart-
ment of Biophysics, Tarbiat Modares University (TMU),
Tehran, Iran. The Ptraj program was used to extract the
information regarding conformational changes and struc-
tural mobility of the structures. In all of the calculations the
protonated form of the ionizable amino acid in pH = 7w a s
used. In order to neutralize the surface charge, positive and
negative ions were added. In case of VHH no ion was added,
but for VHH-SP1 and VHH-SP2, three and one chloride
ions (Cl−) were added, respectively. In the calculations, the
ﬀ03 square force model was used [19], and for computing
electrostatic forces, the Particle-Mesh Ewald (PME) method
was applied [20]. In all simulations, the molecule was placed
in a water environment with the TIP3P water model as
solvent [21], with a minimum solvent shell thickness of 8 ˚ A.
The simulations began with the 5000 iterations of the
energy minimization using the Steepest Descent method.
Simulations were performed for 100-ps under NVT (con-
stant number of particles or moles, volume, and tempera-
ture) conditions, and the temperature increased from 200K
to 300K. Then, the simulations were performed for another
100-ps under NPT (constant number of particles or moles,
pressure, and temperature) conditions so that the system
reached equilibration at constant pressure. (The criteria for
equilibration of the system under NPT conditions included
total energy and density). Simulations continued for 5-ns
under NPT condition and a scale of 2-fs was considered.
In all simulations, the SHAKE algorithm was used to ﬁx
hydrogen bond trembling with other atoms. Finally, every
0.4-ps one structure was saved (in each simulation, 5000
structures were saved for the study).
2.3. Molecular Docking. The calculations regarding the inter-
action between MUC1 and VHH structures, which were
obtained by MD simulations, were performed using 3D-
Dock program. The structure of MUC1 was obtained from
the Protein Data Bank (PDB ID: 1SM3). Docked structures
were constructed using FTDock program [22]. The surface
thickness of VHH was considered as 1.3 ˚ A, and the Rpscore
program was used to score all known complexes. For
each calculation, 100 complexes with the highest score
were selected using the multiDock program. Finally, the
complexes at the lowest energy levels were selected and
compared with each other.
2.4.ConstructionofModiﬁedChimericT-CellReceptor(TCR).
For insertion of the two spacer fragments, CD8α and FcgIIα,
a vector carrying chTCR named pcDNA3.1Hygro+ zeta
CD28IgG3VHHwasused[23].ForobtainingDNAfromthe
two spacer sequences, peripheral white blood cells (WBCs)
were obtained using the Ficoll-Paque solution (Pharmacia,
Sweden), and cells were centrifugedfor20 min at900g. Total
RNA from the WBCs was isolated by the nucleospin RNA
II kit (Macherey-Nagel Duren, Germany), and ﬁrst strandJournal of Biomedicine and Biotechnology 3
cDNA was synthesized with M-MULV reverse transcriptase
(MBI, Fermentas, St. Leon-Rot, Germany). Ampliﬁcation of
the CD28 fragment was carried out by P1 (Table 1)p r i m e r s
using pfu DNA polymerase according to the following
temperature and time proﬁles: 94◦C denaturation for 2min
(1 cycle), 30 cycles each of denaturation at 94◦Cf o r2 0 s ,
annealing at 61◦C for 30s, extension at 72◦C for 1min,
and a ﬁnal extension at 72◦C for 10 min (1 cycle). FcgIIα
ampliﬁcation was carried out using the above-mentioned
material and P2 primers (Table 1) according to the following
temperature and time protocols: 94◦C denaturation for
2min (1 cycle), 30 cycles each of denaturation at 94◦Cf o r
20s,annealingat64.9◦Cfor30s,extensionat72◦Cfor1min,
and a ﬁnal extension at 72◦Cf o r1 0m i n( 1c y c l e ) .
The ampliﬁed CD28 and FcgIIα fragments were sepa-
rated by electrophoresis and puriﬁed from the agarose gel
using the QIA-quick Gel Extraction Kit (Qiagen, Hilden,
Germany). The puriﬁed fragments were then sequenced by
the automated method. In order to cut out the IgG3 spacer
fragment from the original vector carrying the chimeric
cassette and insert the new spacers, the vector was ﬁrst
digested with Not1 (Fermentas) and Xho1 (Fermentas)
enzymes to become linear, and following electrophoresis, the
linearized fragment was puriﬁed using the aforementioned
kit. The linearized fragments were then ligated separately
with the two digested spacer products (CD28 and FcgIIα)
using T4 DNA ligase (TaKaRa, Kyoto, Japan). Two resulting
vectors carrying the diﬀerent spacer fragments were sent
for sequencing to evaluate ligation accuracy. The two con-
structed vectors, pcDNA3.1Hygro+ Zeta CD28 CD8α VHH
and pcDNA3.1Hygro+ Zeta CD28 FcgIIα VHH carrying the
chimeric receptors were designated and pZCCV and pZCFV,
respectively.
2.5.TransfectionofConstructsintoProkaryoticHostandJurkat
Cell Lines. After conﬁrmation of cloning by sequencing,
the two new vectors carrying the CD28 and FcgIIα spacers
were used to transfect the prokaryotic host (TG1), and
following manipulation of the transfected host its DNA was
extracted by QIAprepMiniprep Kit (QIAGEN) according to
the manufacturer’s instructions. Jurkat cells were harvested
at the exponential phase of growth and centrifuged for
10min at 200g. The cells were then resuspended in RPMI
1640 containing 5% fetal calf serum (FCS). Cell numbers
were then counted, and the cells were recentrifuged for
another 5 minutes at 200g. The supernatant was removed,
and the Jurkat cells were resuspended in hypoosmolar
electroporation buﬀer (Eppendorf, Hamburg, Germany).
The cell concentration was adjusted to 1 × 106 cells per
mL. Plasmid DNA (ﬁnal concentration of 10–20μg/mL in
distilled water) was added to the cells and mixed. Samples
of the cell suspensions (400μL) were transferred into elec-
troporation cuvettes with a 2mm gap width (Eppendorf).
Electroporation conditions included one pulse at 240V for
40ms using the Eppendorf system. After the delivery of
the pulse, the cell suspension was allowed to stand in the
cuvette for 5–10min at room temperature. Cells were then
left to recover for 24h in nonselective media, followed by the
selection of transfected cells in 800mg/mL of hygromycin
(Sigma-Aldrich, USA). Selected cells were maintained in
the above media containing the same concentration of
hygromycin for 10 days.
2.6. Reverse Transcriptase PCR (RT-PCR). Total RNA was
isolated from 1 × 106 receptor-grafted and nontransfected
Jurkat cells using the NucleoSpin RNA II system (Macherey-
Nagel GmbH & Co KG). cDNA was synthesized using M-
MuLV as described above. CD28-zeta PCR was performed
using primers P3 (Table 1). It should be noted that intact
Jurkat cells do not express the CD28-zeta chimera. β-
actin was used as an internal control using primers P4
(Table 1). The abovementioned PCR reactions were carried
outaccordingtothefollowingtemperatureandtimeproﬁles:
94◦C denaturation for 5min (1 cycle), 30 cycles each of
denaturation at 94◦C for 20s, annealing at 58◦Cf o r3 0 s ,
extension at 72◦C for 50s, and a ﬁnal extension at 72◦Cf o r
10min (1 cycle).
2.7. Functional Assay of CAR-Grafted Jurkat Cells. Prolif-
eration of CAR-grafted Jurkat cells upon incubation with
MCF7 cells: transfected and nontransfected Jurkat cells
(1 × 105 cells per well) were cocultivated in 6-well plates
with MCF7 tumor cells that had reached 70% conﬂuency.
Nontransfected Jurkat cells and those transfected with the
pCDNA3.1 Hygro+ vector were used as controls. Suspended
cells were harvested after 24h of incubation at 37◦C, and
the collected viable cells (receptor-grafted and control Jurkat
cells) were then counted. Tests were performed in duplicate
wells and transfected and nontransfected Jurkat cells were
counted in duplicate using a Neubauer cell counting cham-
ber (Neubauer, Germany).
2.8. Cytotoxicity Assay. The speciﬁc cytotoxicity of receptor-
grafted and control Jurkat cells against cancerous cells was
measured. In this assay, healthy MCF7 cells were counted in
duplicate as mentioned above, and dead cells were excluded
via staining with trypan blue.
2.9. Designing a Bioassay for Interleukin-2 Secretion. Activity
of the secreted Interleukin-2 (IL-2) in supernatants of the
abovementioned cocultures was assessed in a bioassay test.
In this assay, the proliferation of the IL-2-dependent T-cell
line CTLL2 in the presence of secreted IL-2 was analyzed.
At diﬀerent dilutions of the coculture samples, supernatant
proliferation was assessed by the MTT Cell Viability Assay
Kit (Biotium, Hayward, CA). The 3-[4,5-dimethylthiazol-
2-yl]-2,5-diphenyl tetrazolium bromide (MTT) assay was
performed in 96-well plates. The CTLL2 cell line (1 × 104
cells per well) was cultured in RPMI 1640 medium contain-
ing 15% (v/v) FCS (without IL-2) for 24h. Supernatants
harvested from the two receptor-grafted and control Jurkat
cells cocultured with MCF7 cells were diluted 1:2, 1:4, and
1:9 with fresh RPMI 1640 medium containing 15% (v/v)
FCS and were then added in duplicate to the CTLL2 cells and
incubated at 37◦C for 22h. After incubation, 10mL of the
MTT reagent was added to the wells and incubated for 3h at4 Journal of Biomedicine and Biotechnology
Table 1: Names, properties, and target sequences of PCR primers.
Primer name Sequences Target name
P1 5 CACGCGGCCGCAGCAACTCCATCATGTACTTCAGCCACTTC3 
CD8α
5 AGATGTAGATCTGGAGGGCGAAGTCCAGCCCCCTCGTGTGCAC3 
P2 5 CCTCACGCGGCCGCACTGTCCAAGTGCCCAGCATG3 
FcgIIα
5 TTTTGGCTCGAGCCTGCAGTAGATCAAGGCCAC3 
P3 5 AGAGTGAAGTTCAGCAGGAGC3 
CD28ζ
5 TGCTCTAGATGGCTGTTAGCGAGG3 
P4 5 AGTAGGCTTTGTGGTTGATG3 
β-actin
5 CTGTCAGGAAAGGAGAAATC3 
37◦C. At the end of incubation, the medium was removed,
and 100mL of DMSO (Dimethyl sulfoxide) was then added
to each well to dissolve the formazan crystals by pipetting
up and down several times. Absorbance of each well was
measuredonanELISAplatereaderatawavelengthof540nm
to obtain sample signal.
3. Results
3.1. Theoretical Studies
3.1.1. Molecular Dynamics Simulation. The results from the
theoretical study are presented in four sections: (1) Simu-
lation stability; (2) Structural ﬂuctuation; (3) Simulation of
VHH and MUC1 interaction; (4) Inﬂuence of surface charge
distribution on the interaction.
(1) Simulation Stability. Simulation stability is investigated
in three diﬀerent ways; (a) RMSD; (b) Total energy changes;
(c) Temperature and density.
(a) RMSD. One of the most frequently used measures of
assessing the stability of an MD simulation over the course
of time is the RMSD between the ﬁrst coordinate and the
generated structures in the trajectory, as follows:
RMSD =

1
N

rref
i −r
gen
i

,( 1 )
where rref
i and r
gen
i denote the Cartesian coordinates for
atom i in the ﬁrst and generated structures, respectively.
Therefore, RMSD values for the main chain atoms of VHH,
VHH with the CD8α spacer and VHH with the FcgIIα
spacer during 3ns of the total 5ns simulation time relative
to the experimental structure were calculated (Figure 1(a)).
As revealed in Figure 1, simulation of three structures
showed good stability and no signiﬁcant deviation from
the previous structures after 3ns. We can be sure that the
obtained structures from the simulation were optimal and
that the diﬀerent structural regions aﬀected each other.
Hence, in each simulation, structures reached their ﬁnal
conformations.
(b) Total Energy Changes. Total energy changes during
100ps of simulation time at the equilibrium phase under
NPT conditions were carried out for the certitude ofsimu-
lation stability (Figure 1(b)). As illustrated in Figure 2, the
system’s total energy at the equilibrium phase under ﬁxed
pressure conditions after 20ps for all simulations remains
constant.
(c) Temperature and Density. The temperature for VHH,
VHH with CD8α and VHH carrying FcgIIα was 300K,
and the densities for VHH, VHH with CD8α and VHH
with FcgIIα were 1/03gr/cm3, 1/00gr/cm3, and 1/00gr/cm3,
respectively, that ultimately became ﬁxed and stable, repre-
senting further proof of simulation stability.
(2) Structural Fluctuations. Fluctuation of the interacted
molecules, especially ﬂuctuation of the sequence involved in
the interaction, is of particular importance in the manner
of interaction and protein function eﬃciency. In some
structuralregions,withthepresenceofeachofthetwospacer
sequences, VHH structural ﬂuctuations in the presence of
the CD8α spacer diﬀer signiﬁcantly from that in the presence
of the FcgIIα spacer (Figure 2). It should be mentioned that
the structural properties of the native VHH are considered
as reference properties, and all the investigated properties
in the presence of each spacer sequence in this study are
compared with the reference structure (Figure 2). Regarding
the comparison of the structural ﬂuctuations of native VHH
with that of VHH carrying CD8α,a si l l u s t r a t e di nFigure 2,
theincreasein ﬂuctuationsis in theamino acid regions 5–13,
29–32, 112–117 and a decrease in ﬂuctuations in the amino
acid regions 58–61, 105–110, as compared with the reference
structure. But when comparing the VHH structure carrying
the FcgIIα spacer with that of the reference, the increase in
ﬂuctuations is in the amino acid region 30–36 and a decrease
in ﬂuctuations is in the regions 59–75, 86–96.
(3) Simulation of VHH and MUC1 Interaction. For deno-
tation and comparison of residues involved in interaction,
docking was done between VHH structures, with diﬀerent
spacer, which are obtained from molecular dynamic simula-
tion and target sequence in MUC1 (SAPDTRPAP) (Table 2).
In each simulation 100 complexes were made, and com-
plexes with most negative binding energy, which represent
the important interaction in complexes, were selected. The
results from docking native VHH with MUC1 indicate that
speciﬁc amino acids from VHH participate in interactionJournal of Biomedicine and Biotechnology 5
(a1)
(a2)
(a3)
0
1
2
3
4
5
0 0.5 1 1.5 2 2.5 3
Time (ns)
R
M
S
D
v
a
l
u
e
s
(
A
)
VHH-SP2
0
1
2
3
4
5
0 0.5 1 1.5 2 2.5 3
Time (ns)
R
M
S
D
v
a
l
u
e
s
(
A
)
VHH-SP1
0
1
2
3
4
5
0 0.5 1 1.5 2 2.5 3
Time (ps)
R
M
S
D
v
a
l
u
e
s
(
A
)
VHH
(a)
(b1)
(b2)
(b3)
VHH
−34200
−34000
−33800
−33600
−33400
−33200
−33000
−32800
−32600
0 1 02 03 04 05 06 07 08 09 0 1 0 0
T
o
t
a
l
e
n
e
r
g
y
(
K
c
a
l
/
m
o
l
)
0 1 02 03 04 05 06 07 08 09 0 1 0 0
−98500
−98000
−97500
−97000
−96500
−96000
−95500
T
o
t
a
l
e
n
e
r
g
y
(
K
c
a
l
/
m
o
l
)
VHH-SP1
0 1 02 03 04 05 06 07 08 09 0 1 0 0
VHH-SP2
−80500
−80000
−79500
−79000
−78500
−78000
T
o
t
a
l
e
n
e
r
g
y
(
K
c
a
l
/
m
o
l
)
Time (ps)
Time (ps)
Time (ps)
(b)
Figure 1: Comparison of RMSD and total energy values. RMSD values for the main chain atoms of (a1) VHH, (a2) VHH with CD8α spacer,
and (a3) VHH with FcgIIα spacer during 3ns of a total 5ns simulation time. Total energy changes in 100ps of simulation time for (b1)
VHH, (b2) VHH with CD8α spacer, and (b3) VHH with FcgIIα spacer.
with target. In this simulation important regions involved
in binding include amino acids 41–52, 108–117 with total
binding energy −40.2Kcal/mol. Docking VHH plus CD8α
with MUC1 target sequence showed that regions 5–11, 113–
121 take part in interaction, and total binding energy was
−36.0Kcal/mol. Docking results of VHH plus FcgIIα and
MUC1 target sequence showed that amino acids 4–9, 102–
105, 114–119 are involved and total binding energy was
−46.9Kcal/mol. Interaction simulation results in Table 2
revealed that C-terminal region of VHHs has a critical role
in interacting with MUC1 target sequence. In interaction
VHH-spacer FcgIIα with MUC1 N-terminal region of VHH
and Arg103 are involved in binding and decrease total bind-
ingenergyfrom −40.2to −46.9Kcal/mol.Ontheotherhand
Asp5 in MUC1 target sequence plays an important role in
increasing of binding energy from −40.2 to −36.0Kcal/mol.
(4) Inﬂuence of Surface Charge Distribution on Interaction.
Since the most important factor in the orientation of macro-
molecules perior to interaction is long-range electrostatic
forces, the molecule’s surface charge distribution, which is
the result of charged amino acids in the macromolecules
has signiﬁcant importance. In Figure 3,s u r f a c ec h a r g e
distribution of native VHH and VHH with each of the two
spacers in interaction with the MUC1 target sequence (green
color), especially the pattern of the charged amino acids’
charge distribution in each simulated complex, is shown. It6 Journal of Biomedicine and Biotechnology
Table 2: Binding energy of important residues involved in interaction between MUC1 with the diﬀerent types of VHHs. (Units: Kcal/mol).
Involved residues in binding VHH/MUC1 VHH-SP1/MUC1 VHH-SP2/MUC1
Total VDWa ELEb Total VDW ELE Total VDW ELE
VHH/VHH-sp1/sp2
Glu5 0.0 0.0 0.0 −0.3 −0.1 −0.2 −6.4 −2.0 −4.4
Val6 0.0 0.0 0.0 −0.1 0.0 −0.1 −1.2 −1.2 0.0
Glu7 0.0 0.0 0.0 −6.2 −0.3 −5.9 −1.0 −0.3 −0.7
Gln9 0.0 0.0 0.0 −1.0 −0.8 −0.2 −0.2 0.0 −0.2
Gly48 −0.9 −0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Arg49 −4.2 −2.9 −1.3 0.0 0.0 0.0 0.0 0.0 0.0
Arg103 0.0 0.0 0.0 0.0 0.0 0.0 −2.2 −0.7 −1.5
Leu109 −2.0 −2.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0
Gly110 −1.9 0.7 −2.6 0.0 0.0 0.0 0.0 0.0 0.0
Cys112 −1.6 −0.6 −1.0 0.0 0.0 0.0 0.0 0.0 0.0
Asp113 −1.5 −0.2 −1.3 −0.1 0.0 −0.1 0.0 0.0 0.0
Tyr114 −1.0 −0.7 −0.3 −0.5 −0.5 0.0 −2.7 −1.2 −1.5
Asn115 −2.2 −2.0 −0.2 −0.1 −0.4 0.3 −3.9 −1.6 −2.3
Tyr116 −0.7 −0.8 0.1 −2.7 −2.3 −0.4 −3.9 −2.8 −1.1
Trp117 −0.7 −0.7 0.0 −2.8 −1.9 −0.9 −0.6 −0.5 −0.1
Gln119 0.0 0.0 0.0 −1.1 −0.7 −0.4 0.0 0.0 0.0
MUC1
Pro4 −1.4 −2.0 0.6 −0.3 0.0 −0.3 0.0 0.0 0.0
Asp5 −4.8 −2.6 −2.2 0.0 0.0 0.0 −7.7 −2.9 −4.8
Thr6 −1.0 −0.4 −0.6 −0.8 −0.7 −0.1 −0.3 −0.3 0.0
Arg7 −9.1 −4.2 −4.9 −9.3 −0.5 −8.8 −10.0 −0.7 −9.3
Pro8 −0.3 −0.4 0.1 −2.5 −2.5 0.0 0.0 0.0 0.0
Ala9 −0.5 −0.4 −0.1 −2.4 −2.4 0.0 −2.2 −2.1 −0.1
Pro10 −1.8 −1.8 0.0 −3.1 −2.5 −0.6 −3.2 −2.4 −0.8
aVan der Waals energy, belectrostatic energy.
must be noted that all ﬁgures are shown at a similar viewing
angle.ItcanbeconcludedfromFigures3(c)and3(d)thatthe
VHH molecule is almost a dipole molecule, that is to say that
the charge distribution in the molecule is not equal and the
result is a negatively charged surface (red color) on one face
of the molecule and a positively charged surface on the other
face. The negatively charged surface is a suitable region for
attracting the MUC1 target sequence, which has the arginine
amino acid as the key amino acid. Figures 3(a), 3(b),a n d
3(c) also show little diﬀerence in the surface charge between
the native VHH and VHH with each of the two spacers.
This slight diﬀerence causes change in the orientation of
the MUC1 target sequence during binding, thus leading to
a distinction in binding energy. It should be noted that slight
diﬀerences can signiﬁcantly aﬀect the binding half-life and
eﬀectiveness of the VHH interaction with the MUC1 target
sequence.
3.2. Experimental Studies
3.2.1. Construction and Expression of pZCCV and pZCFV.
Two Chimeric recombinant anti-MUC1 receptors with
diﬀerent spacers, CD8α and FcgIIα, which contain the
anti-MUC1 nanobody were constructed. The two chimeric
receptors contain transmembrane (CD28) and intracellular
(CD3Zeta) moieties, which have been reported previously
[23]. These constructs and the control (vector without the
construct) were transformed into Jurkat cells. Expression
of the transcript was evaluated by RT-PCR using P3 (for
CD28Zeta ampliﬁcation) and P4 (for β-actin, Table 1)
primers (Figure 4).
3.3. Functional Assays
3.3.1. Increased Proliferation of CAR-Grafted Jurkat Cells
upon Coculturing with MCF7 Cells. To monitor the changes
in the growth rate of receptor-grafted Jurkat cells in
the context of antigen simulation, MCF7 cells were co-
cultured with transfected and nontransfected Jurkat cells.
After 24h, recombinant receptor-grafted Jurkat cell prolif-
eration was substantially enhanced upon incubation with
MCF7 tumor cells, while nontransfected Jurkat cells and
pCDNA3.1Hygro+transfectedJurkatcellshadasigniﬁcantly
lower rate of proliferation in the presence of MCF7 tumor
cells (Figure 5).Journal of Biomedicine and Biotechnology 7
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Figure 2: Comparison of structural ﬂuctuation changes of native
VHH with (a) VHH + CD8α,a n d( b )V H H+F c g I I α spacer.
3.4. Cytotoxicity Assay. CAR-grafted Jurkat cells were specif-
ically activated, and the MCF7 cells were lysed with high
eﬃciency, whereas no similar eﬀect was observed in the
nontransfectedJurkatcellsandthecontrolvector-transfected
Jurkat cell culture (Figure 6).
3.5. Determination of Interleukin-2 Secretion. For the bioas-
say, CTLL2 cells were cultured in duplicate in the abovemen-
tioned coculture supernatants harvested from the receptor-
grafted and nontransfected Jurkat cell dilutions. Figure 7
shows the higher proliferation rate of CTLL2 cells in the
receptor-grafted Jurkat cell supernatant. Since the prolifera-
tion of CTLL2 is positively correlated to the IL-2 levels, these
data indicate that receptor-grafted Jurkat cells produce more
IL-2 in comparison with the nontransfected and the control
vector-transfected Jurkat cells (Figure 7).
4. Discussion
T-cell production via genetic engineering of TCR is a new
strategy for immunotherapy. In this method, α and β TCR
genes are transferred to T cells against a speciﬁc antigen.
Since this method does not need the separation of speciﬁc
T cells, it is very functional and applicable. However, the
use of this method has many problems too. TCR recognition
process is MHC dependent. In severe phases of many
cancers, MHC expression is reduced; however, T cells are
available against cancer antigens, but they cannot recognize
tumor cells. Many of the tumor antigens are glycolipids
or carbohydrate antigens, and TCR cannot recognize these
antigens [24, 25].
Another strategy makes use of antibody speciﬁcity to
recognize cancer antigens, cytokine secretion, and killing
of the cells by T lymphocytes. In this method, with the
use of gene constructs containing chimeric T cells, they
gain the ability to recognize diﬀerent cancer antigens. In
such gene constructs, antibody has the role of antigen
recognition(inplaceofTCR),andthepartsthatareremoved
from lymphocyte have the role of signaling domain in T
lymphocytes. Signals in the T lymphocyte ﬁnally lead to
cytotoxic activity [26].
In this study, at ﬁrst, two kinds of chimeric receptor
genesconstructedwithasignalingdomainandcostimulating
molecule were transferred to T-cell lymphocytes. It became
clear that T lymphocytes, beside cytotoxic activity, have
cytokine secretion capability, which can cause a second wave
of stimulations and draw other immune system members to
the tumor site. In subsequent investigations of this study, co-
stimulating and signaling fragments were both placed in an
individual gene construct which ultimately led to favorable
results. Because this method takes advantage of antibody
speciﬁcity, it is MHC independent, and thus this kind of
treatment is unaﬀected by problems associated with low
MHC levels [27].
Furthermore, the use of antibodies in gene constructs
against diﬀerent cancer antigens enables the application
of chimeric receptors to many cancers. In fact, antibodies
have the ability of recognizing glycolipid and carbohydrate
antigens which are common in cancers. Of course chimeric
receptors are not applicable to all cancers, but only to those
inwhichsurfaceantigensarereachableforantibodytargeting
[28].
Many of the accomplished studies have shown that the
usage of chimeric receptors also carries several problems,
such as antiidiotype antibody production, attachment of
few cells to the target tissue and limited distribution in
both healthy and diseased sites. One of the main reasons
for chimeric receptor’s failure during clinical trials is the
immunogenicity of antibody in the receptor. The antibody
usually used in chimeric receptors is ScFv that has a mouse
monoclonal antibody origin. Because of the murine origin
of ScFv, the antibodies that are produced against it disturb
the function of the chimeric receptor. Certainly a great deal
of progress has been achieved to humanize these antibodies,
but they are still at the immunogenic stage [29, 30].
With respect to VHH properties and solving the
immunogenicity of chimeric receptors, this study involved
the use of a gene construct containing the VHH fragment.
This antibody was raised against MUC1 with suitable
properties (Tarbiat Modares University, Iran) [23]. MUC1
is an epithelial membrane mucin, which in its glycosylated
form, covers the gastrointestinal epithelium. Most breast
cancers and many pancreas, colon, ovary, and prostate
adenocarcinomas have increased expression of this antigen
showing a change in its O-glycosylation pattern [31, 32].8 Journal of Biomedicine and Biotechnology
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Figure 3: Surface charge distribution of (a) native VHH, (b) VHH plus spacer 1, (c) VHH plus spacer 2 with MUC1 target sequence, and (d)
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Figure 4: Agarose gel electrophoresis of CD28ζ PCR product.
Lane 1: transfected cells with pZCC and β-actin primers. Lane
2: transfected cells with the pZCC and CD28ζ primers. Lane 3:
transfected cells with the control vector and β-actin primers. Lane
4: transfected cells with control vector and CD28ζ primers. Lane 5:
transfected cells with the pZCF vector and β-actin primers. Lane 6:
transfected cells with the pZCF vector and CD28ζ primers. Lane 7:
negative control. Lane 8: MW DNA size marker (fermentas).
Such proof and evidence, and high expression in a wide
range of MUC1 in cancers, make this molecule a suitable and
proper target for chimeric receptor usage [31]. Therefore,
based on these ﬁndings, this study was divided into two
theoretical and experimental phases. In the theoretical study,
parameters, such as structural conformational changes,
structural ﬂuctuation, and energy of MUC1 interaction
with native VHH and VHH carrying each of the spacer
sequences were investigated to select the most appropriate
spacer sequence. As previously mentioned, the native VHH
structure, when compared to VHH carrying each of the
CD8α and FcgIIα spacers, showed a deviation of 4.13 ˚ A
and 3.67 ˚ A, respectively. These two deviations involving
the binding sequences are related to amino acids 4–11
in VHH plus CD8α and VHH plus FcgIIα,r e s p e c t i v e l y .
Furthermore, deviations of 5.89 ˚ A and 5.39 ˚ A involving the
binding sequence are related to amino acids 105–122 in
b o t hV H Hp l u sC D 8 α and VHH plus FcgIIα. Therefore,
it can be concluded that the deviation level in the binding
sequence of VHH plus FcgIIα is slightly less, thus indicating
a smaller deviation from the native VHH structure, which
suggests that the FcgIIα spacer has a lesser eﬀect on the
ﬁnal VHH conformation. This conformational change in the
binding region can aﬀect the binding pattern and function
of the construct. Another parameter studied was structural
ﬂuctuation which, as mentioned before, changes in the
presence of each spacer, and the pattern of change diﬀers in
the CD8α and FcgIIα spacers.
Structural ﬂuctuations between native VHH and VHH
containing the CD8α spacer showed an increase in ﬂuctua-
tion in the amino acid regions 5–13, 29–32, 112–117, and
a decrease in the amino acids 58–61 and 105–110. These
amino acids correlate with amino acids 5–12, 113–122 at
the binding site of VHH carrying the CD8α spacer and the
MUC1 target sequence, which shows that ﬂuctuation at theJournal of Biomedicine and Biotechnology 9
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Figure 6: Cytotoxicity of MCF7 cells after 24 hours of incubation.
bindingsiteinthepresenceoftheCD8αspacerdemonstrates
a signiﬁcant change. Structural ﬂuctuations between native
VHH and VHH containing the FcgIIα spacer also showed an
increase in ﬂuctuation in the amino acid regions 30–36 and
a decrease in amino acid regions 59–75 and 86–96. These
amino acids do not overlap with the region involved in the
binding of VHH carrying the FcgIIα spacer and the MUC1
target sequence.
As mentioned in the results, the total energy of inter-
action regarding the native VHH, VHH plus CD8α spacer,
and VHH plus FcgIIα with the MUC1 target sequence was
−40.2, −36.0, and −46.9Kcal/mol, respectively. With respect
to the amino acids involved in binding, interactions with
the MUC1 target sequence occur at similar binding sites but
with diﬀerent binding energies. Because the binding energy
of VHH plus FcgIIα with MUC1 is more negative, binding
is stronger and precise due to the conformational changes
of VHH in the presence of the FcgIIα spacer. Hence, it can
be concluded that the FcgIIα spacer is a more appropriate
candidate regarding the CD8α spacer.
Although theoretical studies ascribed the FcgIIα spacer
to be more suitable, its extent of eﬀectiveness on signal
transduction was assessed by experimental procedures. The
fact is that small changes in the aﬃnity and the duration of
connection of the receptor to the related ligand can lead to
remarkable responses in signal transduction; therefore, the
assessment of change in the binding energy generated from
the connection of the ligand to the receptors can be very
useful in the construction of speciﬁc receptors against cancer
antigens.
With extensive studies carried out on chimeric receptors
and the comparison of results obtained from the studies,
the best selections regarding the design of chimeric receptors
were made. Consequently, the CD3Zeta fragment and CD28
were selected as signaling domain and costimulating moiety,
respectively, and CD8α and FcgIIα were selected as spacers
regions. Each spacer sequence was obtained from the NCBI
database, and primers were designed accordingly.
Chimeric receptor expression at the mRNA level in the
transfected cells relative to β-actin as control was found to be10 Journal of Biomedicine and Biotechnology
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
1;2 1;4 1;9
Dilution of coculture supernatant
O
D
a
t
5
4
0
n
m
CAR-grafted Jurkat cell (SP1)
CAR-grafted Jurkat cell (SP2)
pCDNA-grafted Jurkat cell
Figure 7:BioassayresultsforIL-2secretionbythetwoCAR-grafted
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very high, with an absence of response in the untransfected
cells (control cells) and those transfected with the vector
derived from the chimeric receptor (control vector). The
resultsshoweddesirableexpressionandgoodactivityregard-
ing the constructed chimeric receptors, thus conﬁrming the
previous theoretical studies, which showed high levels of
chimeric receptor expression in the cells. Inclusively, the
function of the chimeric receptor was assessed using the
bioassay test. The proliferation of the two recombinant
receptor-grafted Jurkat cells was enhanced upon incubation
with MCF7 tumor cells, while vector-transfected Jurkat cells
had a signiﬁcantly lower rate of proliferation. Furthermore,
the ability of receptor-grafted Jurkat cells to lyse MCF7 cells
was assessed. Receptor-grafted Jurkat cells lysed MCF7 cells
with high eﬃciency, whereas no similar eﬀect was observed
when coculturing with the control vector-transfected Jurkat
cells. Lysis of MCF7 cells in this experiment indicated that
the death of MCF7 cells was receptor dependent, since
the control Jurkat cells were unable to signiﬁcantly induce
MCF7 cell lysis. Jurkat cells secrete IL-2 upon stimulation
and encountering their target antigen. The proliferation
rate of CTLL2 cells in the supernatant of the Jurkat and
MCF7 coculture implies that the receptor-grafted Jurkat
cells produce more IL-2. Since the proliferation of CTLL2
cells is positively correlated to the IL-2 levels, the data
indicate that receptor-grafted Jurkat cells produce more IL-
2 in comparison with the control vector-transfected Jurkat
cells.
The results of theoretical studies indicated that the total
energies of interaction of native VHH, VHH plus CD8α
spacer,andVHHplusFcgIIαwiththeMUC1targetsequence
were −40.2, −36.0, and −46.9Kcal/mol, respectively. So, the
more negative binding energy of VHH plus FcgIIα with
MUC1suggests a much stronger binding. It is predicted that
the eﬀect of an increase in the interaction can more suitably
aﬀect the transduction of signals into the cell for the purpose
of IL2 production.
5. Conclusions
Infact,theresultsfromtheexperimentalphasesupportthese
assumptions and predictions derived from the theoretical
study. However, the striking point is to what extent does
a −10.9Kcal/mol diﬀerence aﬀect the function and eﬀec-
tiveness of chTCR. Experimental results showed that this
slightdiﬀerenceintheinteractionenergycausedasigniﬁcant
increase in receptor eﬀectiveness (the signal transduction
processandIL2).Therefore,priortoanyfunctionalsequence
selection in a chimeric receptor cassette, as in the case of this
study, it is necessary to investigate the simulation stability,
structural ﬂuctuation, interaction simulation and ﬁnally the
charge distribution in the peptide receptor domain, and the
ligand of interest as parameters in theoretical studies.
Nevertheless, the theoretical and experimental results of
thisstudyshowthatdespitealargerspacersizecausingbetter
exposure of the antibody for penetration and accessibility
to membrane antigens in cancer cells (especially antigens
with MUC1 structural properties), the better exposure of
chTCRcannotbetheonlyreasonfortheincreaseinantibody
function regarding interaction with the antigen. In fact, the
better interaction is the consequence of the peptide sequence
eﬀect in the chimeric receptor and enhanced antibody
exposure. With consideration of these results and VHH’s
unique properties, it is hoped that the functional problems
of chimeric receptors can be solved. In order to expand on
the above ﬁndings, it is better to continue the research by
consideringthefollowingitems:(a)substitutionofsignaling,
spacer, and costimulating fragments with other fragments
from other studies and investigation of their functions; (b)
substitutionofVHHagainstMUC1withVHHraisedagainst
other cancer antigens and investigation of their functions;
(c) carrying out mutagenesis of VHH and investigating the
eﬀects of mutations on structural properties and activities
which increase the extent of chTCR binding.
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